oday’s news from Kite Pharma — positive six-month data for patients with severe lymphoma — stokes a blockbuster race that also involves Novartis and Juno Therapeutics, with each angling to carve out a space in what analysts say will be a multibillion-dollar market.

Here’s a breakdown of what happened and what’s to come.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories